Becton Dickinson and (BDX) DIvidends Date & History

Key Takeaways

• Becton, Dickinson and Company (BDX) pays a quarterly dividend of $1.05 per share, translating to an annualized dividend of $4.20 and a current dividend yield of approximately 2.69%.
• BDX is a certified Dividend King and S&P 500 Dividend Aristocrat, having increased its dividend for 53 consecutive years — one of the longest streaks in the entire stock market.
• The most recent dividend increase, announced in November 2024, was 9.5%, reflecting management's confidence in the company's cash flow generation and long-term growth outlook.
• While the trailing earnings-based payout ratio appears elevated, the dividend is well-covered by free cash flow, with a cash flow payout ratio below 35%, indicating strong dividend sustainability.
• BDX offers a balanced dividend profile combining modest current yield with exceptional long-term growth consistency, making it particularly attractive for dividend growth investors.

Dividend Overview

BDX is a leading global medical technology company with a deeply entrenched dividend culture. The company pays a quarterly cash dividend, most recently set at $1.05 per share, resulting in an annualized payout of $4.20. At recent trading levels, this translates to a dividend yield of roughly 2.69%, which sits above the healthcare sector average of approximately 1.66%. The last ex-dividend date was June 9, 2026, with the payment distributed on June 30, 2026. BDX is not a high-yield stock in the traditional sense; instead, it belongs to the rarified category of Dividend Kings, defined as companies that have raised their dividends for at least 50 consecutive years. The company's balanced approach — delivering a respectable current yield paired with an extraordinary track record of annual increases — positions it as a core holding for income-oriented and dividend growth investors alike.

Dividend History and Growth

Becton, Dickinson's dividend track record ranks among the most impressive in corporate America. With 53 consecutive years of annual dividend increases, BDX is one of fewer than 50 publicly traded companies to hold Dividend King status. This streak spans multiple economic cycles, including the inflationary 1970s, the 2008 financial crisis, and the COVID-19 pandemic, underscoring the resilience of the company's business model and its commitment to returning capital to shareholders. Over the past five years, the dividend has grown at a compound annual growth rate (CAGR) of approximately 5.65%. The most recent increase — a 9.5% raise announced alongside fiscal 2024 results in November 2024 — lifted the quarterly payout from $0.95 to $1.04 (and subsequently to $1.05 in late 2025). This acceleration in the growth rate signals management's confidence in BDX's expanding free cash flow and sustained margin improvement.

Dividend Sustainability and Payout Ratio

Dividend sustainability at BDX requires a nuanced look at payout metrics. On a trailing twelve-month GAAP (Generally Accepted Accounting Principles) earnings basis, the payout ratio appears elevated at roughly 106%, which might raise concerns at first glance. However, GAAP earnings can be distorted by non-cash charges, acquisition-related amortization, and one-time items — particularly relevant for a company that recently completed the $4.2 billion acquisition of Edwards Lifesciences' Critical Care product group. When measured against free cash flow — a more meaningful gauge of dividend-paying capacity — the picture looks considerably healthier: BDX's cash flow payout ratio stands at approximately 18% to 34%, indicating ample room for continued dividend growth. In fiscal 2024, the company generated $3.1 billion in free cash flow, a 47.4% increase from the prior year, driven by strong operating performance and improving free cash flow conversion of 82%. Based on forward earnings estimates, the payout ratio is projected to decline to around 30% to 33%, providing a comfortable margin of safety for the dividend.

Dividend Compared to Industry Peers

Within the medical technology sector, BDX's dividend profile stands out for its combination of yield and longevity. For context, ABT (Abbott Laboratories) offers a yield of approximately 1.9% with a similarly strong growth streak, while SYK (Stryker) yields around 1.2% and BSX (Boston Scientific) does not currently pay a dividend. On the higher end, MDT (Medtronic) yields roughly 3.2% and JNJ (Johnson & Johnson) yields about 3.1%. BDX's 2.69% yield places it comfortably in the middle of the peer group, but its 53-year growth streak is unmatched by most competitors. Only JNJ, with over 60 years of consecutive increases, boasts a longer track record among large-cap healthcare names. For dividend investors, BDX represents an attractive middle ground: a yield that outpaces most medical device peers, backed by one of the most durable dividend growth histories in the market.

AI Screener

For investors seeking to identify dividend-paying stocks like BDX alongside other market opportunities, Tickeron's AI Screener provides a powerful, AI-driven stock and ETF discovery platform. The AI Screener allows users to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and fundamental data. Whether searching for consistent dividend growers, high-yield income plays, breakout candidates, or stocks exhibiting specific technical patterns, the screener helps streamline the research process and surface ideas that match an investor's specific strategy. By leveraging AI-powered signals and real-time data, the AI Screener enables more efficient market scanning than traditional manual methods, making it a valuable tool for both active traders and long-term dividend investors looking to uncover their next opportunity.

Is This Stock Attractive for Dividend Investors?

Becton, Dickinson and Company (BDX) is likely to appeal most to dividend growth investors and long-term, conservative income investors who prioritize reliability and compounding over maximum current yield. The 2.69% yield is respectable but not market-leading; the real attraction lies in the extraordinary 53-year track record of annual increases, a distinction held by fewer than 50 publicly traded companies. This consistency makes BDX a plausible candidate for investors building a diversified dividend growth portfolio, including those focused on dividend aristocrat strategies. For pure income seekers who require a high current yield — for example, retirees relying primarily on dividend income — BDX's yield may be insufficient on its own, and higher-yielding names in sectors such as utilities or REITs (Real Estate Investment Trusts) might be more appropriate. The stock may also suit investors who want exposure to the resilient, innovation-driven medical technology sector while earning a growing income stream. As with any equity investment, BDX carries market, sector, and company-specific risks, and its dividend, while historically reliable, is never guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations